Republicans could be viewed unfavorably if HealthCare.gov subsidies were ruled illegal by the Supreme Court, a poll found.» Read More
David Cordani, Cigna president & CEO, weighs in on rival Aetna's wage plan and explains Cigna's growth strategy.
Michelle Berrey, Chimerix CEO, discusses the testing of its Ebola drug Brincidofovir in a clinical setting in West Africa, with CNBC's Meg Tirrell.
Valeant CEO Mike Pearson tells CNBC's Meg Tirrell the company is on a mission to prove allegations against the business model are not true. Pearson says Valeant is unlikely to work with Bill Ackman.
The U.K.’s National Health Service, for decades a global case-study in universal healthcare, seems to be facing its biggest ever crisis of confidence.
Martin D. Sass' stock picks are trades in three popular sectors: airlines, pharmaceuticals and asset management.
Sam Waksal, former Imclone Systems CEO, reveals how the ImClone scandal has impacted his life.
Alex Gorsky, Johnson & Johnson chairman and CEO, discusses how the ACA and the recovery in the economy is impacting business.
Flemming Ornskov, Shire CEO, tells CNBC's Meg TIrrell it is the right time for the proposed acquisition of NPS Pharmaceuticals.
Merck CEO Ken Frazier plans to focus on its specialized area strategy in 2015, with CNCB's Meg Tirrell.
Dr. George Scangos, Biogen Idec CEO, discusses new therapies in multiple sclerosis, Alzheimer's disease and pain.
Dr. David Schenkein, Agios CEO, explains a cancer's metabolism, and the company's priorities for 2015.
Bluebird Bio CEO Nick Leschly, provides insight to how gene therapy can work to treat blood disorders, and sickle cell anemia.
Brent Saunders, Actavis CEO, discusses the deal environment, the process of acquiring Allergan and the good that comes from activist investors.
CNBC's Meg Tirrell speaks to Robert Hugin, Celgene chairman & CEO, about the company's ambitious long-term guidance and broad-based drug pipeline.
CNBC's Meg Tirrell speaks to John Lechleiter, Eli Lilly CEO, about the strength and outlook for the health care sector, and what new drugs he's most excited about.
More and more Americans are "covered," but fewer and fewer Americans will actually be able to get health care, says Jake Novak. Here's why.
The JPMorgan health care conference hadn't even officially begun when the first big piece of news of the week hit: Irish drugmaker Shire said Sunday morning it's purchasing orphan-drug company NPS Pharmaceuticals for $5.2 billion.
Foundation Medicine CEO Michael Pellini tells CNBC, "It's an important day for patients battling cancer."
Healthcare M&A looks set to be strong again this year, following deals from Shire and Roche. But Goldman Sachs says energy's a sector to watch too.
Shire said it will acquire NPS Pharmaceuticals in an all-stock transaction for about $5.2 billion, the companies said on Sunday.
Get the best of CNBC in your inbox